APB CS
Alternative Names: APB-CSLatest Information Update: 03 Apr 2023
At a glance
- Originator APRILBIO
- Class Antineoplastics; Fab fragments; Immunoconjugates
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 31 Mar 2023 Discontinued for Solid tumours in South Korea (Parenteral) before March 2023 (APRILBIO pipeline, March 2023)
- 25 Oct 2021 Early research in Solid tumours in South Korea (Parenteral), before October 2021 (APRILBIO pipeline, October 2021)